Compare QGEN & ATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QGEN | ATR |
|---|---|---|
| Founded | 1986 | 1992 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Plastic Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.3B |
| IPO Year | 1998 | 1995 |
| Metric | QGEN | ATR |
|---|---|---|
| Price | $37.80 | $124.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $50.26 | ★ $170.25 |
| AVG Volume (30 Days) | ★ 1.3M | 357.3K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.03% | 1.54% |
| EPS Growth | N/A | ★ 6.51 |
| EPS | N/A | ★ 5.89 |
| Revenue | N/A | ★ $3,777,181,000.00 |
| Revenue This Year | $8.18 | $5.18 |
| Revenue Next Year | $5.71 | $4.98 |
| P/E Ratio | $24.01 | ★ $21.09 |
| Revenue Growth | N/A | ★ 5.42 |
| 52 Week Low | $38.80 | $103.23 |
| 52 Week High | $57.82 | $164.28 |
| Indicator | QGEN | ATR |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 40.75 |
| Support Level | N/A | $121.12 |
| Resistance Level | $48.53 | $125.35 |
| Average True Range (ATR) | 0.86 | 3.25 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 8.52 | 18.19 |
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.